Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab monotherapy in relapsed/refractory Hodgkin lymphoma not in complete metabolic remission before autologous stem cell transplant
2017-002544-32Phase 2Unknown
- Sponsor
- University College London
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Hodgkin lymphoma (HL), sponsored by University College London. Primary endpoint: Overall response rate by PET-CT after 4–8 cycles of nivolumab. Status: unknown.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2017-002544-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002544-32.